TY  - JOUR
AU  - Nowak, Christoph
AU  - Lind, Marcus
AU  - Sumnik, Zdenek
AU  - Pelikanova, Terezie
AU  - Nattero-Chavez, Lía
AU  - Lundberg, Elena
AU  - Rica, Itxaso
AU  - Martínez-Brocca, Maria A
AU  - Ruiz de Adana, MariSol
AU  - Wahlberg, Jeanette
AU  - Hanas, Ragnar
AU  - Hernandez, Cristina
AU  - Clemente-León, Maria
AU  - Gómez-Gila, Ana
AU  - Ferrer Lozano, Marta
AU  - Sas, Theo
AU  - Pruhova, Stepanka
AU  - Dietrich, Fabricia
AU  - Puente-Marin, Sara
AU  - Hannelius, Ulf
AU  - Casas, Rosaura
AU  - Ludvigsson, Johnny
PY  - 2022
DO  - 10.1210/clinem/dgac343
UR  - http://hdl.handle.net/10668/20398
T2  - The Journal of clinical endocrinology and metabolism
AB  - Residual beta cell function in type 1 diabetes (T1D) is associated with lower risk of complications. Autoantigen therapy with GAD-alum (Diamyd) given in 3 intralymphatic injections with oral vitamin D has shown promising results in persons with T1D...
LA  - en
KW  - C-peptide
KW  - Diamyd
KW  - GAD-alum
KW  - GAD65
KW  - HLA DR3-DQ2
KW  - HbA1c
KW  - antigen-specific immune therapy
KW  - continuous glucose monitoring
KW  - type 1 diabetes
KW  - Adolescent
KW  - Alum Compounds
KW  - Blood Glucose
KW  - Blood Glucose Self-Monitoring
KW  - C-Peptide
KW  - Child
KW  - Diabetes Mellitus, Type 1
KW  - Glutamate Decarboxylase
KW  - Glycemic Control
KW  - HLA-DR3 Antigen
KW  - Humans
KW  - Vitamin D
KW  - Young Adult
TI  - Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2.
TY  - research article
VL  - 107
ER  -